Segall Bryant & Hamill LLC reduced its position in Alkermes plc (NASDAQ:ALKS - Free Report) by 51.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 569,620 shares of the company's stock after selling 613,480 shares during the period. Segall Bryant & Hamill LLC owned about 0.35% of Alkermes worth $16,382,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in ALKS. Loomis Sayles & Co. L P grew its position in Alkermes by 365.5% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company's stock worth $52,704,000 after purchasing an additional 1,478,422 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new position in shares of Alkermes during the third quarter valued at $16,126,000. Raymond James Financial Inc. acquired a new position in Alkermes during the fourth quarter valued at $12,293,000. C WorldWide Group Holding A S purchased a new stake in Alkermes in the 4th quarter worth about $7,190,000. Finally, Barclays PLC boosted its position in Alkermes by 108.8% during the 3rd quarter. Barclays PLC now owns 423,931 shares of the company's stock worth $11,867,000 after acquiring an additional 220,893 shares during the period. Institutional investors and hedge funds own 95.21% of the company's stock.
Insiders Place Their Bets
In related news, EVP Craig C. Hopkinson sold 100,918 shares of Alkermes stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total value of $3,234,421.90. Following the sale, the executive vice president now owns 44,290 shares of the company's stock, valued at approximately $1,419,494.50. This trade represents a 69.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.89% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the stock. UBS Group raised shares of Alkermes from a "sell" rating to a "neutral" rating and increased their price target for the stock from $21.00 to $38.00 in a research report on Tuesday, March 4th. StockNews.com upgraded shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Royal Bank of Canada started coverage on shares of Alkermes in a research note on Thursday, March 13th. They issued a "sector perform" rating and a $40.00 price target on the stock. HC Wainwright restated a "neutral" rating and set a $46.00 price target on shares of Alkermes in a research note on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Alkermes from $40.00 to $52.00 and gave the stock a "buy" rating in a report on Thursday. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Alkermes has an average rating of "Moderate Buy" and an average target price of $39.38.
Check Out Our Latest Report on ALKS
Alkermes Trading Down 1.0 %
Shares of ALKS stock traded down $0.32 on Friday, hitting $33.21. The stock had a trading volume of 922,403 shares, compared to its average volume of 1,751,921. The firm has a market cap of $5.40 billion, a P/E ratio of 15.30, a PEG ratio of 2.20 and a beta of 0.62. Alkermes plc has a twelve month low of $22.90 and a twelve month high of $36.45. The company has a fifty day moving average price of $33.45 and a two-hundred day moving average price of $30.29.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. On average, analysts expect that Alkermes plc will post 1.31 earnings per share for the current year.
About Alkermes
(
Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
See Also
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
